Company Overview and News

Kirkland Lake Gold (KL) Presents At European Gold Forum - Slideshow

2018-04-18 seekingalpha
The following slide deck was published by Kirkland Lake Gold Ltd. in conjunction with this event.
Upvote Downvote

Veolia to deliver water treatment plant at gold mine

Kirkland Lake Gold has awarded Veolia Water Technologies a contract to design and supply a reverse osmosis plant to reduce the chloride levels in the water stream at the Fosterville gold mine in Victoria.
Upvote Downvote

Kirkland Lake Gold: More Juice In The Rally

2018-04-16 seekingalpha
Strong financial growth likely in FY18 backed by higher gold prices, marginally higher production and lower AISC.
Upvote Downvote

THIS Market Has Changed And Forever - ValueWalk

2018-04-16 valuewalk
“The world clings to its old mental picture of the stock market because it’s comforting; because it’s so hard to draw a picture of what has replaced it; and because the few people able to draw it for you have no interest in doing so.”
Upvote Downvote

Kirkland Lake Gold Announces Details of Annual General Meeting and First Quarter 2018 Conference Call and Webcast 

2018-04-15 globenewswire
TORONTO, April 15, 2018 (GLOBE NEWSWIRE) -- Kirkland Lake Gold Ltd. (“Kirkland Lake Gold” or the “Company”) (TSX:KL) (NYSE:KL) (ASX:KLA) today announced that the Company will hold its Annual General Meeting (the “Meeting”) of Shareholders at 10:00 am ET on Wednesday May 2, 2018 at the TSX Exchange Tower located at 130 King Street West, Toronto, Ontario, M5X 1C9. A webcast of the Meeting will be available on the Company’s website at www.
Upvote Downvote

Trade of the Day: Kirkland Lake Gold Ltd (KL)

2018-04-13 investorplace
To receive further updates on this Kirkland Lake Gold Ltd (NYSE:KL) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
Upvote Downvote

7 A-Rated Materials Stocks to Buy | InvestorPlace

2018-04-13 investorplace
Materials stocks run the gamut. But whether a firm is making steel, refining oil and gas or making distilled spirits, the fact is, in an expanding economy these companies are in very good positions.
Upvote Downvote

Kirkland Lake Gold posts quarterly production growth of 13%

Following on from posting record-breaking quarterly and annual company results in January, Kirkland Lake Gold has released its latest quarterly (Q1) figures, showing growth of 13 per cent compared with Q1 results for the previous year.
Upvote Downvote

BRIEF-Kirkland Lake Gold Says 147,644 Ounces Produced In Q1 2018, An Increase Of 13 Pct

2018-04-06 reuters
Upvote Downvote

Kirkland Lake Gold Reports Strong Year-Over-Year Q1 Production Growth

2018-04-06 globenewswire
TORONTO, April 06, 2018 (GLOBE NEWSWIRE) -- Kirkland Lake Gold Ltd. (“Kirkland Lake Gold” or the “Company”) (TSX:KL) (NYSE:KL) (ASX:KLA) today announced solid quarterly production for the first quarter of 2018 (“Q1 2018”). A total of 147,644 ounces was produced in Q1 2018, an increase of 13% from the first quarter of 2017 (“Q1 2017”). Q1 2018 production exceeded target levels for the quarter, driven by record monthly production in March of 71,615 ounces, which largely reflected positive grade performance at both Fosterville and Macassa.
Upvote Downvote

Kirkland Lake Gold Files Technical Report

2018-04-03 globenewswire
TORONTO, April 02, 2018 (GLOBE NEWSWIRE) -- Kirkland Lake Gold Ltd. (“Kirkland Lake Gold” or the “Company”) (TSX:KL) (NYSE:KL) (ASX:KLA) today announced the filing of a technical report for the Company’s Fosterville property (the “Report”) entitled, “Report on the Mineral Resources & Mineral Reserves of the Fosterville Gold Mine in the State of Victoria, Australia.” The Report, which is dated April 2, 2018 and is effective December 31, 2017, was prepared in compliance with National Instrument 43-101 - Standards for Disclosure for Mineral Projects ("NI 43-101") and is available under Kirkland Lake Gold's profile on SEDAR at www.
Upvote Downvote

GDXJ: The Market's Best Risk Play?

2018-03-29 seekingalpha
Dividend stocks work well in these environments, but income portfolios will also need some added measure of safety if further “flash crashes” are seen this year.
Upvote Downvote

Sierra Metals - A Turnaround Year

2018-03-27 seekingalpha
Generally, for many years it was a single-mine company but this year we should see big improvements at Sierra's Mexican operations.
Upvote Downvote

Hecla Acquires Klondex: A Short Discussion Of The Deal

2018-03-19 seekingalpha
According to the announcement, Hecla is going to purchase all Klondex assets located in Nevada; the Canadian assets will be spun out to the current Klondex shareholders.
Upvote Downvote

Franco-Nevada's (FNV) CEO David Harquail on Q4 2017 Results - Earnings Call Transcript

2018-03-10 seekingalpha
Good morning. My name is Chris and I will be your conference operator today. At this time, I would like to welcome everyone to the Franco-Nevada Corporation Fourth Quarter Results Conference Call. All lines have been placed mute to prevent background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...